This work is a primary step in combining gene therapy and immunotherapy, where CRAds designed to produce anti-PD-1 antibodies directly in the tumor microenvironment enable the T cells to kill the tumor cells and bypass the side effects of the systemic administration of anti-PD-1 sdAbs [25]. This evidence concerns the gene PDCD1 and neoplasm.